이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

A Randomized, Double-Blind, Placebo-Controlled Trial of Fufei Huazhuo Tongluo Formula Combined With Standardized Medicine in Patients With Anti-Synthetase Syndrome-Associated Interstitial Lung Disease

2026년 9월 17일 업데이트: First People's Hospital of Hangzhou

A Prospective, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Pragmatic Clinical Trial of Fufei Huazhuo Tongluo Formula Combined With Standardized Western Medicine for Glucocorticoid-Sparing Efficacy in Patients With Anti-Synthetase Syndrome-Associated Interstitial Lung Disease

The goal of this clinical trial is to learn if the traditional Chinese medicine formula "FuFei HuaZhuo TongLuo Granule" combined with standardized western medicine works to treat anti-synthetase syndrome-associated interstitial lung disease (ASS-ILD). It will also learn about the safety of this combined therapy. The main questions it aims to answer are:

Does the Chinese herbal formula plus standardized western medicine increase the proportion of patients who successfully reduce their glucocorticoid dose to a low maintenance level (prednisone ≤ 7.5 mg/day) at 24 weeks, compared with placebo plus standardized western medicine?

Does this herbal formula provide additional clinical benefits in terms of glucocorticoid sparing, delaying lung function decline, reducing infection risk, and improving traditional Chinese medicine syndrome scores?

What medical problems do participants have when taking this herbal formula?

Researchers will compare the Chinese herbal granule to a placebo granule (a look-alike substance that contains no active ingredients) to see if the herbal formula works to treat ASS-ILD. Both groups will receive standardized western medicine treatment based on disease severity.

Participants will:

Take the Chinese herbal granule or a placebo every day for 12 weeks

Visit the clinic at 8 time points: baseline, weeks 2, 4, 8, 12, 16, 20, and 24 for checkups and tests

Undergo pulmonary function tests (at baseline, week 12, and week 24) and high-resolution CT scans (at baseline, week 12, and week 24)

Receive disease activity assessments (MITAX score), traditional Chinese medicine syndrome evaluations, and safety monitoring (blood routine, liver and kidney function, adverse event recording) at each follow-up visit

Provide peripheral blood samples at weeks 0, 4, 12, and 24 for exploratory immunology and metabolomics research

Record their daily glucocorticoid dosage and concomitant medications throughout the study

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

상세 설명

Background Anti-synthetase syndrome (ASS) is an autoimmune disease characterized by anti-aminoacyl-tRNA synthetase (ARS) antibodies and represents a major subtype of idiopathic inflammatory myopathy (IIM). Its clinical manifestations are heterogeneous, frequently involving the lungs, muscles, joints, and skin. Interstitial lung disease (ILD) is the most common and characteristic organ involvement, occurring in over 80% of patients and often presenting as the initial manifestation. In some patients, ASS-ILD follows a rapidly progressive course (RP-ILD), leading to acute respiratory failure within weeks or even days, with a 1-year survival rate of approximately 75%, making it a leading cause of critical illness and early death in rheumatology.

Current Western medical treatment for ASS-ILD relies on potent immunosuppression, primarily high-dose glucocorticoids combined with conventional immunosuppressants (e.g., cyclosporine, tacrolimus, cyclophosphamide). Biologics targeting B cells (rituximab) and JAK inhibitors have also been recommended for severe or refractory cases. However, long-term high-dose glucocorticoid and immunosuppressant use presents two major challenges: difficulty in tapering without disease relapse-rapid reduction often triggers pulmonary flares, while slow tapering increases cumulative toxicity, resulting in low successful tapering rates to safe doses within 24-40 weeks in real-world practice-and significant treatment-related toxicity, with exponentially increased risk of opportunistic infections (e.g., Pneumocystis jirovecii pneumonia, invasive fungal infections, cytomegalovirus infection).

In traditional Chinese medicine (TCM), ASS-ILD is classified as "lung impediment"or "lung atrophy". Based on long-term clinical experience, our group proposes that the core pathogenesis is "deficiency of lung collaterals as the root, with damp-heat, phlegm, and blood stasis as the manifestations." In the early stage, pathogenic heat and dampness obstruct the lung collaterals; as the disease progresses, chronic involvement leads to phlegm-stasis obstruction and eventually "collateral stasis with accumulation," which corresponds to reticular opacities, fibrotic nodules, and linear shadows on imaging. Guided by the principle of "unblocking collaterals to restore function," we developed the original Chinese herbal formula FuFei HuaZhuo TongLuo Granule (composed of Danggui, Qianghuo, Yinchen, Fangfeng, Cangzhu, Baizhu, Zhimu, Shengma, Gegen, Huangqin, Yiyiren, Ezhu, Dilong, Jiangcan, Gancao, etc.). Preliminary pilot and retrospective studies suggest that this formula may improve dyspnea, control TCM syndrome scores, facilitate glucocorticoid tapering, and reduce opportunistic infections.

Objectives The primary objective is to evaluate the rate of successful safe glucocorticoid (prednisolone or equivalent) tapering to a low maintenance dose (≤7.5 mg/day) at 24 weeks with the herbal formula plus standardized Western medicine, compared with placebo plus standardized Western medicine. Secondary objectives include exploring the clinical benefits on TCM syndrome scores, disease activity, reduction of Western drug side effects, and preservation of lung function; and investigating potential molecular targets and mechanisms through immunomics and multi-omics analyses of peripheral blood and other biospecimens.

Study Design Overview This is a single-center, randomized, double-blind, placebo-controlled pragmatic clinical trial (PCT). A total of 54 eligible patients will be enrolled and randomized in a 2:1 ratio using block randomization (stratified by baseline disease severity) to either the integrative medicine group (herbal plus standardized Western medicine) or the Western medicine alone group (placebo plus standardized Western medicine). The intervention consists of daily granule administration for 12 weeks, with a total follow-up of 24 weeks. There are 8 clinical visits: baseline (week 0) and weeks 2, 4, 8, 12, 16, 20, and 24. At each follow-up visit, all patients undergo disease activity assessment (MITAX score), traditional Chinese medicine (TCM) syndrome differentiation analysis, and safety monitoring, including complete blood count, liver and renal function tests, and adverse event recording. Peripheral blood samples are collected at weeks 0, 4, 12, and 24 for immunology and metabolomics research. Pulmonary function tests and high-resolution computed tomography (HRCT) scans are performed at baseline, week 12, and week 24. Throughout the study, daily glucocorticoid dosage and concomitant medications are recorded.

연구 유형

중재적

등록 (추정된)

54

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria: (1) Western medicine diagnostic criteria: meeting the 2017 EULAR/ACR classification criteria for idiopathic inflammatory myopathy, with positive anti-synthetase antibodies (e.g., anti-Jo-1, PL-7, PL-12, etc.), and confirmed interstitial lung disease (ILD) by high-resolution computed tomography (HRCT). (2) Traditional Chinese Medicine (TCM) syndrome differentiation criteria: meeting the criteria for either "damp-heat obstructing collaterals syndrome" or "collateral stasis with accumulation syndrome." Damp-heat obstructing collaterals syndrome: satisfying 2 major symptoms + 1 minor symptom + tongue and pulse manifestations, or 1 major symptom + 2 minor symptoms + tongue and pulse manifestations (major symptoms include heavy and aching muscles, joint aching, cough and wheezing with profuse phlegm, etc.; red tongue with yellow, greasy coating, and slippery, rapid pulse). Collateral stasis with accumulation syndrome: satisfying 2 major symptoms + 1 minor symptom + tongue and pulse manifestations, or 1 major symptom + 2 minor symptoms + tongue and pulse manifestations (major symptoms include stabbing muscle pain and weakness, fixed joint pain, shortness of breath and panting, etc.; dark tongue with ecchymotic spots, greasy coating, and deep, wiry or slippery pulse). (3) Age and sex: 18-70 years of age, both sexes eligible. (4) At screening, in a state of newly diagnosed or relapsed ASS-ILD, and receiving a glucocorticoid dose of ≥30 mg/day prednisone (or equivalent). (5) Informed consent: the patient or his/her legal representative voluntarily signs the written informed consent form.

Exclusion Criteria: (1) Concomitant other severe diseases: other active connective tissue diseases (e.g., SLE, RA, pSS, etc.); severe non-rheumatic cardiovascular diseases (e.g., uncontrolled heart failure, recent myocardial infarction), malignancy, or severe hepatic/renal dysfunction (ALT/AST > 3× ULN, Cr > 1.5× ULN). (2) Respiratory failure: At baseline, the presence of any one of the following criteria is defined as respiratory failure, and the patient should be excluded: Type I respiratory failure: at sea level and at rest, arterial blood gas showing PaO₂ < 60 mmHg with PaCO₂ ≤ 50 mmHg; Type II respiratory failure: at sea level and at rest, arterial blood gas showing PaO₂ < 60 mmHg with PaCO₂ > 50 mmHg. If the patient is already receiving high-flow oxygen therapy or non-invasive/invasive mechanical ventilation, respiratory failure is considered present regardless of blood gas values, and the patient should be excluded. (3) Interference from recent treatment history: receipt of hematopoietic stem cell transplantation within the past 3 months; continuous use of other systemic Chinese herbal decoctions or granules within 2 weeks before enrollment. (4) Special populations: pregnant or breastfeeding women. (5) Psychiatric or cognitive impairment: presence of severe psychiatric illness or cognitive impairment that prevents cooperation with clinical follow-up and assessments.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Experimental: Chinese Herbal Formula plus Standardized Western Medicine

Participants receive FuFei HuaZhuo TongLuo Granule (one dose daily, orally, for 12 weeks) along with standardized Western medicine (glucocorticoids plus conventional immunosuppressants) adjusted according to a disease severity-based protocol.

FuFei HuaZhuo TongLuo Granule is a traditional Chinese medicine formulation provided as oral granules. One dose (divided into two equal portions) is taken orally in the morning and evening daily for 12 consecutive weeks. The granule contains the following herbal ingredients: Danggui, Qianghuo, Yinchen, Fangfeng, Cangzhu, Baizhu, Zhimu, Shengma, Gegen, Huangqin, Yiyiren, Ezhu, Dilong, Jiangcan, Gancao.

위약 비교기: Placebo Comparator: Placebo plus Standardized Western Medicine

Participants receive matching Placebo Granule (one dose daily, orally, for 12 weeks) along with the same standardized Western medicine protocol as the experimental arm.

Matching Placebo Granule is provided as oral granules with identical appearance, taste, odor, packaging, and labeling to the FuFei HuaZhuo TongLuo Granule. It contains inactive ingredients and is taken orally, one dose (divided into two equal portions) in the morning and evening daily for 12 consecutive weeks.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Proportion of Participants Achieving Glucocorticoid Tapering to ≤7.5 mg/day at Week 24
기간: Week 24

Percentage of participants who successfully reduce their prednisone (or equivalent) maintenance dose to ≤7.5 mg/day at Week 24, without disease flare (as defined by objective pulmonary or imaging progression) and without initiating protocol-defined escalated salvage therapy.

Week 24

2차 결과 측정

결과 측정
측정값 설명
기간
Cumulative Glucocorticoid Exposure Over 24 Weeks
기간: Baseline up to Week 24

Area under the curve (AUC) of total glucocorticoid dose accumulated over the 24-week follow-up period.

Baseline up to Week 24
Proportion of Participants with ≥50% Reduction in Traditional Chinese Medicine Syndrome Score
기간: Baseline and Week 24

Proportion of participants achieving at least a 50% reduction from baseline in the total Traditional Chinese Medicine (TCM) syndrome score at Week 24.

Baseline and Week 24
Proportion of Participants with Stable or Improved Forced Vital Capacity (FVC)
기간: Baseline and Week 24

Proportion of participants with FVC% predicted value showing a decline of less than 5% from baseline (i.e., stable or improved) at Week 24.

Baseline and Week 24
Incidence of Severe Opportunistic Infections Requiring Hospitalization
기간: Up to Week 24

Cumulative incidence of severe opportunistic infections (e.g., Pneumocystis jirovecii pneumonia, invasive fungal infections, cytomegalovirus infection) requiring hospitalization over the 24-week follow-up period.

Up to Week 24

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 10월 10일

기본 완료 (추정된)

2028년 7월 1일

연구 완료 (추정된)

2028년 12월 31일

연구 등록 날짜

최초 제출

2026년 9월 17일

QC 기준을 충족하는 최초 제출

2026년 9월 17일

처음 게시됨 (실제)

2026년 9월 23일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 23일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 17일

마지막으로 확인됨

2026년 7월 1일

추가 정보

이 연구와 관련된 용어

추가 관련 MeSH 약관

기타 연구 ID 번호

  • GZY-KJS-ZJ-2026-136

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .